Drugs / NTP42
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04919863 | May 2021 → Jan 2022 | — | ATXA Therapeutics Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NTP42 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04919863 ↗ |
| Action | Inhibit | “The thromboxane receptor (TP) antagonist NTP42” PMID 38178863 ↗ Dec 2023 |
| Route | Oral | “NTP42, administered as the oral formulation NTP42:KVA4” PMID 38178863 ↗ Dec 2023 |